Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Solazyme: Key Takeaways And Insights From The Q1 2014 Results

On May 5, renewable oils and bioproducts producer, Solazyme (SZYM) announced its Q1 2014 earnings results. The company saw year-over-year revenue growth of 85% but also experienced increasing losses of 39% in light of a recent launch of commercial operations and an extended ramping phase to nameplate capacity. The following are five key takeaways that investors should consider from Solazyme's Q1 2014 conference call:

    Initial production for Moema expected in Q2 2014. While the negative ramifications of a possible delay have often been exaggerated, the delay of the company's 100,000 MT facility will likely push initial production into May or early June. Despite this announcement, it is important to understand that the company's 625,000-L production...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details